scholarly journals Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

2013 ◽  
Vol 2 (2) ◽  
pp. 112-120 ◽  
Author(s):  
Gregory L. Beatty ◽  
Andrew R. Haas ◽  
Marcela V. Maus ◽  
Drew A. Torigian ◽  
Michael C. Soulen ◽  
...  
Keyword(s):  
T Cells ◽  
Antitumor Activity ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Receptor Mrna ◽  
Solid Malignancies ◽  
Engineered T Cells

scholarly journals Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

2013 ◽  
Vol 1 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Evripidis Lanitis ◽  
Mathilde Poussin ◽  
Alex W. Klattenhoff ◽  
Degang Song ◽  
Raphael Sandaltzopoulos ◽  
...  
Keyword(s):  
T Cells ◽  
Antitumor Activity ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Signaling Domains

scholarly journals Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2343-2354 ◽  
Author(s):  
Saar Gill ◽  
Sarah K. Tasian ◽  
Marco Ruella ◽  
Olga Shestova ◽  
Yong Li ◽  
...  
Keyword(s):  
T Cells ◽  
Acute Myeloid Leukemia ◽  
Mouse Models ◽  
Chimeric Antigen Receptor ◽  
Myeloid Leukemia ◽  
Antigen Receptor ◽  
Key Points ◽  
Human Acute Myeloid Leukemia ◽  
Engineered T Cells ◽  
Acute Myeloid

Key Points Targeting of CD123 via CAR-engineered T cells results in rejection of human AML and myeloablation in mouse models.

Graded potency of chimeric antigen receptor (CAR)-engineered T cells for cancer immunotherapy.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3022-3022
Author(s):  
Michel Sadelain ◽  
Maud Condomines ◽  
Zeguo Zhao ◽  
Renier J. Brentjens ◽  
Isabelle Riviere
Keyword(s):  
T Cells ◽  
Cancer Immunotherapy ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Engineered T Cells
Sign in / Sign up

Export Citation Format

Share Document